DGAM Healthcare Growth
Scaling Innovative Healthcare Champions
A buyout strategy dedicated to healthcare, Daniel Global Asset Management Ltd Healthcare Growth seeks to scale healthcare companies by building commercial muscle and expanding their global reach to generate attractive risk-adjusted returns while simultaneously delivering positive outcomes across the healthcare value chain.
Control investments in innovative, profitable healthcare companies with a strong growth outlook.
The acceleration of innovation, driven by strong secular growth factors, is expanding the opportunity to invest in innovative healthcare products and services that address the increasing demand for improved, more efficient, and accessible healthcare. Against this backdrop, DGAM Healthcare Growth invests in mid-market opportunities in the same sub-sectors as DGAM Equity, building on that strategy’s three-decade track record.
The dedicated DGAM Healthcare Growth team is supported by an active Investment Committee including relevant senior DGAM leaders and is an integral part of DGAM’s global healthcare sector vertical and the broader Private Capital platform. The team combines the deep scientific expertise and ability to identify emerging trends from DGAM Life Sciences with DGAM Equity’s value-creation playbook and 30-year track record in healthcare investing.
DGAM’s 30-year healthcare track record
Spotlight On Healthcare Growth
Opinion
Investors Must Put Patient Outcomes Ahead of Short-Term Gains
Healthcare
5 Things Investors Should Know About Healthcare
The Transformative Impact of Healthcare Companies
Explore Our Portfolio
A leading European distributor of specialty life science reagents, enabling cutting-edge scientific research
Europa Biosite connects innovative suppliers with researchers across Europe and North America, providing specialised reagents and consumables critical for life science research
Key Facts
Sector Life Science Tools and Diagnostics
Country Sweden
Fund DGAM Healthcare Growth
Entry 2025
Website europabiosite.com
A Swedish biotech company developing immunoassays for life science research
Since 1986, Mabtech’s mission has been to aid research by providing the global scientific community with innovative tools. To that end, the company generates and produces a wide range of monoclonal antibodies, kits, peptide pools, and instruments for in vitro applications.
Key Facts
Sector Biotech
Country Sweden
Fund DGAM Healthcare Growth
Entry 2024
Responsible advisors Rikke Kjær Nielsen
Website mabtech.com
A leading European distributor of specialty life science reagents, enabling cutting-edge scientific research
Europa Biosite connects innovative suppliers with researchers across Europe and North America, providing specialised reagents and consumables critical for life science research
Key Facts
Sector Life Science Tools and Diagnostics
Country Sweden
Fund DGAM Healthcare Growth
Entry 2025
Website europabiosite.com
The DGAM Future Team
Maarten De Jong
Head of Healthcare Growth
Geraldine O'Keeffe
Partner
Isabel De Paoli
Partner
Mark Braganza
Partner
Mark Wegter
Partner
Pascal Noel
Director
Madeleine Magnerius
Director
Philip How Aarhus
Director
Do You Want to Know More?
We are eager to explore how we can achieve great things together.
